Article Text
PDF
Abstract
Background Angiotensin receptor-neprilysin inhibitors (ARNi) and sodium-glucose co-transporter 2 inhibitors (SGLT2i) have a Class I indication in the European Society of Cardiology's guidelines for the diagnosis and treatment of acute and chronic heart failure due to benefits in symptom management, rehospitalization rates, and mortality in heart failure. The aim of this study was to investigate demographic, geographic and socioeconomic disparities in prescriptions for ARNi and SGLT2i for heart failure patients in a universal healthcare system.
Methods We used national registers to identify all Danish heart failure patients who were diagnosed on or after the updated clinical guidelines by the European Society of Cardiology (14 July 2016 for ARNi and 27 August 2021 for SGLT2i). Patients were followed until redemption of prescription, emigration, death or censoring on 30 June 2022, whichever came first. The Aalen-Johansen estimator and Cox proportional hazard models were used for individual analysis of ARNi (n=43 625) and SGLT2i (n=2819).
Results The following factors were associated with lack of prescriptions for ARNi and SGLT2i: being women, older age, living alone and being non-native Danish or descendant. HRs ranged from 0.31 (95% CI 0.28 to 0.36) to 0.86 (95% CI 0.80 to 0.93) for ARNi and 0.49 (95% CI 0.41 to 0.58) to 0.93 (95% CI 0.72 to 1.20) for SGLT2i. Prescriptions for both ARNi and SGLT2i showed a social gradient, with the gradient for ARNi being statistically significant.
Conclusions Substantial disparity was found in prescriptions for the potentially life-saving medications, with lack of prescriptions being associated with lower education, lower income and several demographic characteristics.
- Heart Failure
- Health Care Economics and Organizations
Data availability statement
Data may be obtained from a third party and are not publicly available. The individual-level data used for this study are not publicly available. However, the data can be obtained by application to The Danish Health Data Authority (www.sundhedsdatastyrelsen.dk) and Statistics Denmark (https://www.dst.dk/en) for researchers affiliated with an authorised Danish research environment.
Statistics from Altmetric.com
Data availability statement
Data may be obtained from a third party and are not publicly available. The individual-level data used for this study are not publicly available. However, the data can be obtained by application to The Danish Health Data Authority (www.sundhedsdatastyrelsen.dk) and Statistics Denmark (https://www.dst.dk/en) for researchers affiliated with an authorised Danish research environment.
Footnotes
X @Christensen_MK
Contributors RS and JEM acquired funding for the study. MKC, RS and JEM designed the study. MKC and VBH prepared the data for analysis. MKC analysed the data and wrote the first draft of the paper. MKC, RS, JEM, CM, VBH and AKP interpreted the data and contributed to the writing of the paper. All authors revised and approved the final version. MKC is the guarantor of the manuscript.
Funding This study received funding from the Independent Research Fund Denmark under the grant ID: 10.46540/2034-00296B.
Competing interests None declared.
Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.